{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T22:16:07Z","timestamp":1792880167698,"version":"4.5.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>No studies have examined the effect of mineralocorticoid receptor antagonist therapy on new-onset diabetes. In addition, though the combination of diabetes and chronic heart failure (CHF) carries a poor prognosis, few studies have examined predictors of new-onset diabetes in those with CHF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>In patients with symptomatically mild CHF who participated in the placebo-controlled Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure, we examined the effect of the aldosterone antagonist, eplerenone, on physician-diagnosed diabetes using univariate Cox proportional hazard analysis. To identify predictors of new-onset diabetes (measures of glycaemia were not available), data from trial arms were combined and multivariate Cox proportional hazard analyses and receiver operating characteristic curve analyses were conducted. At baseline, the mean age of 1846 initially non-diabetic patients was 69 years and mean left ventricular ejection fraction was 26%. Over 21 months, 69 (3.7%) developed diabetes (33 on eplerenone, 36 on placebo). Eplerenone had no effect on new-onset diabetes [hazard ratio (HR) 0.94, 95% confidence interval (CI) 0.59\u20131.52] and no effect on the composite of new-onset diabetes or mortality (HR 0.80, 95% CI 0.64\u20131.01). Independent predictors of new-onset diabetes included digoxin therapy, higher serum alanine aminotransferase, longer duration of heart failure, current or previous smoker, higher waist circumference, lower age, and higher systolic blood pressure with a combined c-statistic of 0.74.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Eplerenone had no effect on new-onset diabetes in patients with CHF, but further large-scale studies are required to address this question comprehensively. Commonly recorded parameters provided useful information for predicting new-onset diabetes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurjhf\/hfs067","type":"journal-article","created":{"date-parts":[[2012,5,20]],"date-time":"2012-05-20T11:27:05Z","timestamp":1337513225000},"page":"909-915","source":"Crossref","is-referenced-by-count":71,"title":["Eplerenone and New-Onset Diabetes in Patients with Mild Heart Failure: Results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF)"],"prefix":"10.1093","volume":"14","author":[{"given":"David","family":"Preiss","sequence":"first","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow , Glasgow, G12 8TA ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk J.","family":"van Veldhuisen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Thorax Center, University Medical Center , Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveed","family":"Sattar","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow , Glasgow, G12 8TA ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Krum","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Preventive Medicine, Centre of Cardiovascular Research and Education in Therapeutics, Monash University , Melbourne ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Swedberg","sequence":"additional","affiliation":[{"name":"Department of Emergency and Cardiovascular Medicine, Sahlgrenska Academy, University of Gothenburg , Gothenburg ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"Shi","sequence":"additional","affiliation":[{"name":"Pfizer , New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Vincent","sequence":"additional","affiliation":[{"name":"Pfizer , New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart J.","family":"Pocock","sequence":"additional","affiliation":[{"name":"Department of Medical Statistics, London School of Hygiene and Tropical Medicine , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertram","family":"Pitt","sequence":"additional","affiliation":[{"name":"University of Michigan School of Medicine , Ann Arbor, MI ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[{"name":"INSERM, Centre d'Investigation Clinique 9501 and Unit\u00e9 961, Centre Hospitalier Universitaire, and the Department of Cardiology, Nancy University , Nancy ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.V.","family":"McMurray","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow , Glasgow, G12 8TA ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2014,2,18]]},"reference":[{"key":"2026011921173526200_ejhfhfs067-bib-0001","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1093\/eurheartj\/ehn156","article-title":"Diabetes, left ventricular systolic dysfunction, and chronic heart failure","volume":"29","author":"MacDonald","year":"2008","journal-title":"Eur Heart J"},{"key":"2026011921173526200_ejhfhfs067-bib-0002","doi-asserted-by":"crossref","first-page":"915","DOI":"10.2337\/dc08-1709","article-title":"Predictors of development of diabetes in patients with chronic heart failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) program","volume":"32","author":"Preiss","year":"2009","journal-title":"Diabetes Care"},{"key":"2026011921173526200_ejhfhfs067-bib-0003","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1136\/hrt.2006.092379","article-title":"Scherhag A; COMET investigators. Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET)","volume":"93","author":"Torp-Pedersen","year":"2007","journal-title":"Heart"},{"key":"2026011921173526200_ejhfhfs067-bib-0004","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0140-6736(07)60108-1","article-title":"Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis","volume":"369","author":"Elliott","year":"2007","journal-title":"Lancet"},{"key":"2026011921173526200_ejhfhfs067-bib-0005","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa1001121","article-title":"Effect of valsartan on the incidence of diabetes and cardiovascular events","volume":"362","author":"McMurray","year":"2010","journal-title":"N Engl J Med"},{"key":"2026011921173526200_ejhfhfs067-bib-0006","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1161\/CIRCULATIONAHA.104.528166","article-title":"Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity Program Investigators. Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure","volume":"112","author":"Yusuf","year":"2005","journal-title":"Circulation"},{"key":"2026011921173526200_ejhfhfs067-bib-0007","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.ahj.2010.04.024","article-title":"Effect of eplerenone versus spironolactone on cortisol and hemoglobin A(c) levels in patients with chronic heart failure","volume":"160","author":"Yamaji","year":"2010","journal-title":"Am Heart J"},{"key":"2026011921173526200_ejhfhfs067-bib-0008","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/j.metabol.2006.07.025","article-title":"The effect of spironolactone on circulating adipocytokines in patients with type 2 diabetes mellitus complicated by diabetic nephropathy","volume":"55","author":"Matsumoto","year":"2006","journal-title":"Metabolism"},{"key":"2026011921173526200_ejhfhfs067-bib-0009","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1007\/s00125-004-1510-8","article-title":"Spironolactone impairs endothelial function and heart rate variability in patients with type 2 diabetes","volume":"47","author":"Davies","year":"2004","journal-title":"Diabetologia"},{"key":"2026011921173526200_ejhfhfs067-bib-0010","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1007\/s00125-008-0972-5","article-title":"Spironolactone for poorly controlled hypertension in type 2 diabetes: conflicting effects on blood pressure, endothelial function, glycaemic control and hormonal profiles","volume":"51","author":"Swaminathan","year":"2008","journal-title":"Diabetologia"},{"key":"2026011921173526200_ejhfhfs067-bib-0011","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1177\/1470320311402110","article-title":"Effect of spironolactone and vitamin E on serum metabolic parameters and insulin resistance in patients with nonalcoholic fatty liver disease","volume":"12","author":"Polyzos","year":"2011","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"2026011921173526200_ejhfhfs067-bib-0012","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/eurjhf\/hfq049","article-title":"Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS-HF)","volume":"12","author":"Zannad","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"2026011921173526200_ejhfhfs067-bib-0013","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Pitt B; EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"2026011921173526200_ejhfhfs067-bib-0014","article-title":"Diabetes Data and Trends","author":"Centers for Disease Control and Prevention","year":"2009"},{"key":"2026011921173526200_ejhfhfs067-bib-0015","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1210\/jc.2009-2521","article-title":"Aldosterone production and insulin resistance in healthy adults","volume":"95","author":"Garg","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"2026011921173526200_ejhfhfs067-bib-0016","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1210\/jc.2006-0736","article-title":"Insulin sensitivity in patients with primary aldosteronism: a follow-up study","volume":"91","author":"Catena","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"2026011921173526200_ejhfhfs067-bib-0017","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.jcmg.2011.08.014","article-title":"A randomized study of the beneficial effects of aldosterone antagonism on LV function, structure, fibrosis markers in metabolic syndrome","volume":"4","author":"Kosmala","year":"2011","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026011921173526200_ejhfhfs067-bib-0018","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1007\/s00125-010-2029-9","article-title":"Low serum potassium levels and risk of type 2 diabetes: the Toranomon Hospital Health Management Center Study 1 (TOPICS 1)","volume":"54","author":"Heianza","year":"2011","journal-title":"Diabetologia"},{"key":"2026011921173526200_ejhfhfs067-bib-0019","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/jhh.2008.41","article-title":"Predictors of new-onset diabetes mellitus in hypertensive patients: the VALUE trial","volume":"22","author":"Aksnes","year":"2008","journal-title":"J Hum Hypertens"},{"key":"2026011921173526200_ejhfhfs067-bib-0020","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.2337\/diabetes.53.11.2855","article-title":"Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, C-reactive protein in the west of Scotland coronary prevention study","volume":"53","author":"Sattar","year":"2004","journal-title":"Diabetes"},{"key":"2026011921173526200_ejhfhfs067-bib-0021","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2337\/dc08-1870","article-title":"Alanine aminotransferase, gamma-glutamyltransferase, incident diabetes: the British Women's Heart, Health Study, meta-analysis","volume":"32","author":"Fraser","year":"2009","journal-title":"Diabetes Care"},{"key":"2026011921173526200_ejhfhfs067-bib-0022","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1159\/000074814","article-title":"Functional capacity impairment in patients with coronary artery disease: prevalence, risk factors and prognosis","volume":"100","author":"Tenenbaum","year":"2003","journal-title":"Cardiology"},{"key":"2026011921173526200_ejhfhfs067-bib-0023","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00000441-200701000-00001","article-title":"Animal and human tissue Na, K-ATPase in obesity and diabetes: a new proposed enzyme regulation","volume":"333","author":"Iannello","year":"2007","journal-title":"Am J Med Sci"},{"key":"2026011921173526200_ejhfhfs067-bib-0024","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.pathophys.2007.09.003","article-title":"Endogenous sodium pump inhibitors, diabetes mellitus and preeclampsia. Preliminary observations and a hypothesis","volume":"14","author":"Bagrov","year":"2007","journal-title":"Pathophysiology"},{"key":"2026011921173526200_ejhfhfs067-bib-0025","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/dmrr.728","article-title":"Predicting the 20-year diabetes incidence rate","volume":"23","author":"Dankner","year":"2007","journal-title":"Diabetes Metab Res Rev"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1093%2Feurjhf%2Fhfs067","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1093%2Feurjhf%2Fhfs067","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1093\/eurjhf\/hfs067","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1093\/eurjhf\/hfs067","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/14\/8\/909\/66442453\/eurjhf_14_8_909.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/14\/8\/909\/66442453\/eurjhf_14_8_909.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T02:23:08Z","timestamp":1768875788000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/14\/8\/909\/8428916"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,1]]},"references-count":25,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2014,2,18]]},"published-print":{"date-parts":[[2012,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/eurjhf\/hfs067","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2012,8]]},"published":{"date-parts":[[2012,8,1]]}}}